<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL</h1>
  <ul>
<li>Serious ARs occurred in 56% of patients.</li>
<li>Sepsis (6%) and febrile neutropenia (4%) occurred.</li>
<li>Mantle Cell Lymphoma Serious ARs occurred in 38% of patients.</li>
<li>The most frequent malignancy was non-melanoma skin cancer (4.6%).</li>
<li>Bleeding of any grade, excluding bruising and petechiae, occurred (17%).</li>
<li>ARs resulting in permanent discontinuation in &gt;1% of patients included pneumonia.</li>
<li>Grade 4 decreased neutrophils (14%) and Grade 4 decreased platelets (6%) developed.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-first-only-104500259.html">Source</a> · 2025-09-08T10:45:00+00:00</p>
</body>
</html>